Mark L. Baum: Yes. As I said the reason for our enthusiasm is twofold. One because of what we have which is exceptional. So we have a great product. But our enthusiasm is buttressed by the competition that we face. And so, on the one hand, you may look at the products that are in the market and say there’s a lot of them. But if you’re a dry eye patient and you have pain in your eye you’re feeling grittiness and redness and you’re aggravated and it’s hard to work. And you go to put a product in your eye and 22% of the patients experience pain when you instill a product in your eye or the adverse event profile even get worse than that for some of the products that are in development. So, you’re that patient and you need something that soothes your pain.
I don’t think that these products that live in the so-called water world are really helping them. And we have a totally unique different approach. And as I said I personally have put an EyeSol product in my eye on my eye and there’s just nothing that feels like it. And having listened to literally hundreds of interviews of chronic dry eye disease patients, I just think we have something that’s going to really benefit them. Not on the margin like some of the existing products may benefit patients. But we’re talking about in a completely new way something that doesn’t have that burning and stinging it doesn’t cause dysgeusia. It doesn’t cause pain at instillation something you don’t have to spray up your nose or doesn’t cause sneezing when you put it up your nose.
This is a different approach. And we’re going to patiently execute strategy to make sure patients have access to VEVYE. It is a totally new world. It’s the water-free world.
Mayank Mamtani: Got it. And maybe just last one for Andrew. Is there sort of a target range for leverage ratio you’re trying to get to in the near to medium term. Obviously it’s improved but is there some — is there a sort of range you’re working towards Andrew?
Andrew Boll: I think that’s a good question and thanks for that. We — it depends is the answer. And I think what I mean by that is we’re obviously sort of deal focused in our DNA. And so if there are transactions that we can transact on and lever into it we’re not going to pass it up. And so that’s what I’m saying is we’re not going to and obviously it’s got to be an attractive deal to do that. But to the current just based on the current leverage ratio, especially on an annualized basis, I personally would like to see it lower. We’re definitely working towards that. I think if you see it in the guidance even our expectation is EBITDA is going to continue to grow throughout the year in order for us to hit the guidance number. But at the same time, we like to use debt as a way to fund these transactions if there are additional transactions for us to do. We’ll do that and we’ll take advantage of the instrument and our partners on the debt side.
Mayank Mamtani: Understood. Makes a lot of sense. Thanks again for taking our questions.
Andrew Boll: Thank you, Mayank.
Operator: The next question is from Jim Roumell of Roumell Asset Management. Please go ahead.
Jim Roumell: Thanks. Just a quick question. New to the story but been following it. Your net equity dropped nearly 20% in the quarter. I haven’t had a chance to look at really the pushes and the pulls, but can you give a little color as to kind of what decisions you’re — balance sheet decisions you’re making, expansion of credit for growth. But just a little color on why your net equity dropped nearly 20% in the quarter — or in the first half of the year?
